| European Case Law Identifier: | ECLI:EP:BA:2011:T084007.20110914 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 14 September 2011 | ||||||||
| Case number: | T 0840/07 | ||||||||
| Application number: | 02777137.7 | ||||||||
| IPC class: | C07K 14/705 A61K 38/18 A61P 37/06 |
||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | C | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Peptides capable of modulating immune response | ||||||||
| Applicant name: | CellAct Pharma GmbH | ||||||||
| Opponent name: | - | ||||||||
| Board: | 3.3.04 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Unity of invention (yes) Remittal (yes) Reimbursement of appeal fee (no) |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t070840eu1.html
Date retrieved: 17 May 2021